 Tomi Pastinen
Concepts (650)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 40 | 2023 | 108 | 5.130 |
Why?
| | Polymorphism, Single Nucleotide | 62 | 2022 | 340 | 4.920 |
Why?
| | Genomics | 18 | 2024 | 86 | 4.840 |
Why?
| | Alleles | 37 | 2024 | 197 | 4.000 |
Why?
| | Gene Expression Regulation | 30 | 2021 | 98 | 3.430 |
Why?
| | Humans | 163 | 2024 | 6599 | 3.430 |
Why?
| | Gene Expression Profiling | 28 | 2021 | 109 | 3.300 |
Why?
| | Genome-Wide Association Study | 38 | 2022 | 181 | 3.110 |
Why?
| | Genetic Variation | 27 | 2020 | 161 | 2.930 |
Why?
| | Genome, Human | 19 | 2021 | 82 | 2.870 |
Why?
| | Rare Diseases | 4 | 2024 | 37 | 2.820 |
Why?
| | Quantitative Trait Loci | 26 | 2022 | 64 | 2.550 |
Why?
| | Sequence Analysis, DNA | 21 | 2023 | 106 | 2.250 |
Why?
| | Epigenomics | 13 | 2020 | 26 | 2.050 |
Why?
| | Epigenesis, Genetic | 24 | 2022 | 64 | 2.030 |
Why?
| | CpG Islands | 23 | 2022 | 51 | 1.820 |
Why?
| | Genetic Predisposition to Disease | 33 | 2021 | 215 | 1.780 |
Why?
| | Chromosome Mapping | 14 | 2024 | 33 | 1.690 |
Why?
| | Privacy | 2 | 2023 | 2 | 1.540 |
Why?
| | Information Dissemination | 2 | 2023 | 8 | 1.530 |
Why?
| | High-Throughput Nucleotide Sequencing | 12 | 2023 | 94 | 1.480 |
Why?
| | Regulatory Sequences, Nucleic Acid | 10 | 2019 | 16 | 1.480 |
Why?
| | Osteoblasts | 8 | 2015 | 21 | 1.440 |
Why?
| | Haplotypes | 15 | 2023 | 81 | 1.380 |
Why?
| | Female | 63 | 2023 | 3436 | 1.290 |
Why?
| | Male | 61 | 2023 | 3197 | 1.290 |
Why?
| | Polymorphism, Genetic | 13 | 2018 | 89 | 1.220 |
Why?
| | T-Lymphocytes | 6 | 2021 | 31 | 1.190 |
Why?
| | Adult | 33 | 2024 | 1233 | 1.070 |
Why?
| | Mutation | 14 | 2023 | 194 | 1.040 |
Why?
| | Asthma | 12 | 2020 | 143 | 1.010 |
Why?
| | Chromatin | 7 | 2021 | 20 | 1.010 |
Why?
| | Child | 27 | 2023 | 3146 | 1.010 |
Why?
| | Middle Aged | 32 | 2021 | 648 | 1.010 |
Why?
| | Sequence Analysis, RNA | 5 | 2020 | 23 | 1.000 |
Why?
| | Insurance Coverage | 1 | 2023 | 19 | 0.900 |
Why?
| | Histones | 3 | 2021 | 15 | 0.880 |
Why?
| | Genotype | 29 | 2019 | 395 | 0.870 |
Why?
| | Cell Line | 15 | 2023 | 80 | 0.850 |
Why?
| | Respiratory Insufficiency | 1 | 2022 | 12 | 0.840 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2022 | 13 | 0.840 |
Why?
| | Bone Density | 10 | 2015 | 43 | 0.800 |
Why?
| | Transcription, Genetic | 10 | 2017 | 44 | 0.790 |
Why?
| | Phenotype | 17 | 2023 | 233 | 0.790 |
Why?
| | Vitamin B 12 | 6 | 2022 | 9 | 0.780 |
Why?
| | Gene Expression | 10 | 2020 | 60 | 0.740 |
Why?
| | Animals | 21 | 2024 | 563 | 0.720 |
Why?
| | Aged | 23 | 2021 | 375 | 0.710 |
Why?
| | DNA Mutational Analysis | 6 | 2016 | 36 | 0.710 |
Why?
| | Arthritis, Rheumatoid | 5 | 2021 | 9 | 0.710 |
Why?
| | Transcriptome | 6 | 2023 | 50 | 0.670 |
Why?
| | Oligonucleotide Array Sequence Analysis | 11 | 2015 | 45 | 0.670 |
Why?
| | Neurodevelopmental Disorders | 3 | 2024 | 19 | 0.670 |
Why?
| | Enhancer Elements, Genetic | 7 | 2021 | 18 | 0.660 |
Why?
| | Base Sequence | 12 | 2023 | 76 | 0.630 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 7 | 0.630 |
Why?
| | Autoimmune Diseases | 6 | 2021 | 11 | 0.630 |
Why?
| | Software | 4 | 2017 | 24 | 0.590 |
Why?
| | Carrier Proteins | 6 | 2018 | 32 | 0.570 |
Why?
| | MicroRNAs | 4 | 2020 | 26 | 0.560 |
Why?
| | Adolescent | 18 | 2023 | 2087 | 0.560 |
Why?
| | Genetic Privacy | 1 | 2015 | 2 | 0.540 |
Why?
| | Gene Regulatory Networks | 8 | 2019 | 15 | 0.540 |
Why?
| | Gene Frequency | 12 | 2018 | 88 | 0.530 |
Why?
| | Membrane Proteins | 7 | 2013 | 50 | 0.520 |
Why?
| | Pedigree | 9 | 2023 | 53 | 0.520 |
Why?
| | Spermatozoa | 3 | 2020 | 5 | 0.510 |
Why?
| | Genomic Imprinting | 2 | 2011 | 7 | 0.490 |
Why?
| | Genetic Diseases, Inborn | 3 | 2011 | 18 | 0.490 |
Why?
| | Organ Specificity | 7 | 2018 | 22 | 0.480 |
Why?
| | Allelic Imbalance | 6 | 2012 | 7 | 0.470 |
Why?
| | RNA, Messenger | 8 | 2017 | 107 | 0.470 |
Why?
| | Intellectual Disability | 2 | 2024 | 31 | 0.470 |
Why?
| | Genetic Testing | 4 | 2021 | 74 | 0.440 |
Why?
| | Reproducibility of Results | 5 | 2024 | 197 | 0.440 |
Why?
| | Promoter Regions, Genetic | 8 | 2021 | 47 | 0.430 |
Why?
| | Medicine | 2 | 2023 | 10 | 0.430 |
Why?
| | Lymphocytes | 5 | 2015 | 15 | 0.430 |
Why?
| | Neoplasms | 2 | 2011 | 119 | 0.430 |
Why?
| | Linkage Disequilibrium | 10 | 2018 | 34 | 0.430 |
Why?
| | Herpes Simplex | 2 | 2023 | 10 | 0.430 |
Why?
| | Monocytes | 4 | 2016 | 9 | 0.420 |
Why?
| | Genetics, Medical | 1 | 2011 | 5 | 0.420 |
Why?
| | Fractures, Bone | 5 | 2015 | 35 | 0.420 |
Why?
| | Brain Neoplasms | 3 | 2019 | 44 | 0.410 |
Why?
| | Breast Neoplasms | 3 | 2016 | 38 | 0.400 |
Why?
| | Diabetes Mellitus, Type 1 | 4 | 2019 | 108 | 0.390 |
Why?
| | Mice | 10 | 2023 | 290 | 0.390 |
Why?
| | Osteoporosis | 5 | 2012 | 25 | 0.390 |
Why?
| | Adipose Tissue | 4 | 2019 | 27 | 0.390 |
Why?
| | Neutrophils | 3 | 2021 | 11 | 0.390 |
Why?
| | Environmental Exposure | 1 | 2011 | 27 | 0.390 |
Why?
| | Graft vs Host Disease | 3 | 2019 | 11 | 0.390 |
Why?
| | Cell Line, Tumor | 6 | 2019 | 87 | 0.380 |
Why?
| | Neoplasm Proteins | 5 | 2023 | 29 | 0.380 |
Why?
| | Biomarkers, Tumor | 4 | 2018 | 61 | 0.380 |
Why?
| | Folic Acid | 3 | 2019 | 16 | 0.370 |
Why?
| | Fibroblasts | 6 | 2018 | 26 | 0.370 |
Why?
| | Child, Preschool | 12 | 2021 | 1459 | 0.370 |
Why?
| | Probability | 1 | 2009 | 17 | 0.360 |
Why?
| | Risk Factors | 13 | 2018 | 460 | 0.360 |
Why?
| | Metabolic Diseases | 2 | 2019 | 11 | 0.350 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2019 | 50 | 0.350 |
Why?
| | Trans-Activators | 2 | 2021 | 11 | 0.350 |
Why?
| | Repressor Proteins | 3 | 2017 | 12 | 0.340 |
Why?
| | Genetic Loci | 8 | 2018 | 37 | 0.330 |
Why?
| | RNA, Long Noncoding | 3 | 2018 | 14 | 0.330 |
Why?
| | Cells, Cultured | 7 | 2018 | 73 | 0.330 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2019 | 6 | 0.330 |
Why?
| | Genome | 4 | 2022 | 30 | 0.330 |
Why?
| | Heterozygote | 5 | 2018 | 23 | 0.330 |
Why?
| | Homeodomain Proteins | 3 | 2017 | 18 | 0.320 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2017 | 14 | 0.320 |
Why?
| | Molecular Sequence Data | 7 | 2014 | 65 | 0.320 |
Why?
| | Computational Biology | 4 | 2018 | 40 | 0.320 |
Why?
| | DNA | 7 | 2015 | 39 | 0.310 |
Why?
| | Exome | 3 | 2016 | 34 | 0.310 |
Why?
| | Drosophila Proteins | 2 | 2024 | 7 | 0.310 |
Why?
| | DNA Primers | 4 | 2000 | 27 | 0.310 |
Why?
| | Precision Medicine | 4 | 2020 | 42 | 0.310 |
Why?
| | Metabolism, Inborn Errors | 2 | 2018 | 6 | 0.310 |
Why?
| | Aged, 80 and over | 9 | 2020 | 150 | 0.300 |
Why?
| | Immune System Diseases | 2 | 2016 | 6 | 0.300 |
Why?
| | Cell Lineage | 2 | 2018 | 17 | 0.300 |
Why?
| | Coronary Artery Disease | 2 | 2019 | 10 | 0.290 |
Why?
| | Rhinitis, Allergic | 2 | 2017 | 10 | 0.290 |
Why?
| | Chromatin Immunoprecipitation | 2 | 2017 | 8 | 0.280 |
Why?
| | Expressed Sequence Tags | 1 | 2005 | 1 | 0.280 |
Why?
| | Young Adult | 8 | 2021 | 652 | 0.270 |
Why?
| | Infant | 8 | 2023 | 1396 | 0.270 |
Why?
| | Histocompatibility Testing | 4 | 2019 | 22 | 0.260 |
Why?
| | Genetic Markers | 5 | 2012 | 20 | 0.260 |
Why?
| | HLA-B Antigens | 2 | 2022 | 7 | 0.250 |
Why?
| | Finland | 10 | 2015 | 11 | 0.250 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2016 | 60 | 0.250 |
Why?
| | Antibodies, Viral | 2 | 2022 | 46 | 0.250 |
Why?
| | Case-Control Studies | 8 | 2020 | 202 | 0.250 |
Why?
| | Multiple Sclerosis | 5 | 2003 | 18 | 0.240 |
Why?
| | Homocystinuria | 2 | 2022 | 3 | 0.240 |
Why?
| | Exons | 4 | 2013 | 32 | 0.240 |
Why?
| | Cerebellar Ataxia | 1 | 2023 | 4 | 0.240 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2023 | 1 | 0.240 |
Why?
| | Folic Acid Deficiency | 1 | 2023 | 2 | 0.240 |
Why?
| | Neuroaxonal Dystrophies | 1 | 2023 | 2 | 0.240 |
Why?
| | Attitude | 1 | 2023 | 12 | 0.240 |
Why?
| | Transcription Factors | 4 | 2018 | 46 | 0.230 |
Why?
| | Cell Differentiation | 3 | 2018 | 41 | 0.230 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2023 | 3 | 0.230 |
Why?
| | Herpesvirus 1, Human | 1 | 2023 | 4 | 0.230 |
Why?
| | Interferon Type I | 1 | 2023 | 5 | 0.230 |
Why?
| | Lactation | 1 | 2023 | 5 | 0.230 |
Why?
| | Epilepsy | 1 | 2023 | 14 | 0.230 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 24 | 0.230 |
Why?
| | Drug Therapy | 2 | 2013 | 7 | 0.230 |
Why?
| | Milk, Human | 1 | 2023 | 21 | 0.230 |
Why?
| | Muscular Atrophy, Spinal | 1 | 2023 | 2 | 0.230 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2023 | 20 | 0.230 |
Why?
| | Intracellular Signaling Peptides and Proteins | 4 | 2024 | 18 | 0.230 |
Why?
| | Cardiovascular System | 1 | 2022 | 4 | 0.230 |
Why?
| | Eosinophils | 2 | 2020 | 28 | 0.230 |
Why?
| | Urinary Tract | 1 | 2022 | 6 | 0.230 |
Why?
| | Polymerase Chain Reaction | 6 | 2001 | 82 | 0.220 |
Why?
| | Viral Vaccines | 1 | 2022 | 10 | 0.220 |
Why?
| | Sulfites | 2 | 2020 | 4 | 0.220 |
Why?
| | Human Growth Hormone | 1 | 2022 | 15 | 0.220 |
Why?
| | Molecular Sequence Annotation | 3 | 2016 | 9 | 0.210 |
Why?
| | Growth Disorders | 1 | 2022 | 24 | 0.210 |
Why?
| | HLA-B7 Antigen | 1 | 2022 | 2 | 0.210 |
Why?
| | HLA-C Antigens | 1 | 2022 | 3 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2019 | 51 | 0.210 |
Why?
| | Dexamethasone | 3 | 2015 | 30 | 0.210 |
Why?
| | Genetic Association Studies | 3 | 2020 | 53 | 0.210 |
Why?
| | Parents | 1 | 2023 | 149 | 0.210 |
Why?
| | Nasal Mucosa | 1 | 2021 | 8 | 0.210 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 1 | 0.200 |
Why?
| | Tetralogy of Fallot | 1 | 2021 | 2 | 0.200 |
Why?
| | Bone and Bones | 3 | 2015 | 16 | 0.200 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 17 | 0.200 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 2 | 2015 | 13 | 0.200 |
Why?
| | Monomeric GTP-Binding Proteins | 1 | 2021 | 2 | 0.200 |
Why?
| | Body Height | 2 | 2011 | 31 | 0.200 |
Why?
| | Egg Proteins | 2 | 2012 | 3 | 0.200 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 19 | 0.200 |
Why?
| | Dermatitis, Atopic | 1 | 2020 | 7 | 0.200 |
Why?
| | Poly A | 1 | 2020 | 1 | 0.200 |
Why?
| | Algorithms | 3 | 2018 | 103 | 0.200 |
Why?
| | Colorectal Neoplasms | 2 | 2018 | 27 | 0.200 |
Why?
| | RNA, Ribosomal | 1 | 2020 | 3 | 0.200 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2020 | 26 | 0.190 |
Why?
| | Markov Chains | 2 | 2018 | 8 | 0.190 |
Why?
| | Aging | 1 | 2020 | 32 | 0.190 |
Why?
| | Immune System | 2 | 2017 | 4 | 0.190 |
Why?
| | Child Abuse | 1 | 2021 | 45 | 0.190 |
Why?
| | Pregnancy | 4 | 2023 | 203 | 0.180 |
Why?
| | Hematopoietic Stem Cells | 2 | 2016 | 22 | 0.180 |
Why?
| | Hypersensitivity | 1 | 2020 | 51 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 9 | 0.180 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2020 | 11 | 0.180 |
Why?
| | Bone Morphogenetic Protein 2 | 2 | 2011 | 4 | 0.180 |
Why?
| | Membrane Transport Proteins | 2 | 2023 | 12 | 0.180 |
Why?
| | Genetic Techniques | 1 | 2019 | 5 | 0.180 |
Why?
| | Graft vs Leukemia Effect | 1 | 2019 | 1 | 0.180 |
Why?
| | Phospholipid Transfer Proteins | 1 | 2019 | 1 | 0.180 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2019 | 11 | 0.180 |
Why?
| | Epistasis, Genetic | 2 | 2018 | 4 | 0.180 |
Why?
| | Microtubule-Associated Proteins | 2 | 2018 | 5 | 0.180 |
Why?
| | Protein Processing, Post-Translational | 2 | 2021 | 6 | 0.180 |
Why?
| | Chromosomes, Human, Pair 17 | 3 | 2020 | 6 | 0.180 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2013 | 6 | 0.180 |
Why?
| | Oxidoreductases | 5 | 2022 | 9 | 0.180 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2019 | 7 | 0.170 |
Why?
| | Histone Code | 4 | 2021 | 6 | 0.170 |
Why?
| | RNA | 2 | 2015 | 14 | 0.170 |
Why?
| | Glioblastoma | 1 | 2019 | 17 | 0.170 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 3 | 0.170 |
Why?
| | DNA Transposable Elements | 2 | 2017 | 2 | 0.170 |
Why?
| | Chromosomes, Human | 1 | 2018 | 2 | 0.170 |
Why?
| | Germinal Center | 1 | 2018 | 1 | 0.170 |
Why?
| | Codon, Nonsense | 1 | 2018 | 6 | 0.170 |
Why?
| | Hodgkin Disease | 1 | 2018 | 2 | 0.170 |
Why?
| | Myocardial Infarction | 1 | 1998 | 5 | 0.170 |
Why?
| | Hematologic Neoplasms | 1 | 2018 | 1 | 0.170 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 14 | 0.170 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 64 | 0.170 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 96 | 0.170 |
Why?
| | Cluster Analysis | 3 | 2020 | 43 | 0.170 |
Why?
| | Receptors, CCR5 | 1 | 1998 | 1 | 0.170 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 49 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 33 | 0.170 |
Why?
| | HLA Antigens | 1 | 2018 | 12 | 0.160 |
Why?
| | Genes, Regulator | 2 | 2015 | 4 | 0.160 |
Why?
| | PAX7 Transcription Factor | 1 | 2018 | 1 | 0.160 |
Why?
| | Peroxiredoxins | 1 | 2018 | 1 | 0.160 |
Why?
| | HIV-1 | 1 | 1998 | 31 | 0.160 |
Why?
| | Stroke | 1 | 2018 | 24 | 0.160 |
Why?
| | Transcriptional Elongation Factors | 1 | 2017 | 2 | 0.160 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2017 | 4 | 0.160 |
Why?
| | Multiple Myeloma | 1 | 2017 | 4 | 0.160 |
Why?
| | Hindlimb | 1 | 2017 | 1 | 0.160 |
Why?
| | Organogenesis | 1 | 2017 | 1 | 0.160 |
Why?
| | Paired Box Transcription Factors | 1 | 2017 | 1 | 0.160 |
Why?
| | Scleroderma, Systemic | 1 | 2017 | 1 | 0.150 |
Why?
| | Models, Genetic | 4 | 2018 | 33 | 0.150 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 2 | 0.150 |
Why?
| | Primates | 1 | 2017 | 2 | 0.150 |
Why?
| | Conserved Sequence | 1 | 2017 | 5 | 0.150 |
Why?
| | Supervised Machine Learning | 1 | 2017 | 2 | 0.150 |
Why?
| | Gene Ontology | 3 | 2021 | 6 | 0.150 |
Why?
| | RNA, Untranslated | 1 | 2017 | 6 | 0.150 |
Why?
| | Immediate-Early Proteins | 1 | 2017 | 2 | 0.150 |
Why?
| | Databases, Genetic | 3 | 2018 | 25 | 0.150 |
Why?
| | Dietary Supplements | 2 | 2015 | 18 | 0.150 |
Why?
| | Stem Cells | 1 | 2017 | 19 | 0.150 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2016 | 2 | 0.150 |
Why?
| | Human Genome Project | 1 | 2016 | 3 | 0.150 |
Why?
| | Genes, BRCA2 | 1 | 2016 | 5 | 0.150 |
Why?
| | Genes, BRCA1 | 1 | 2016 | 6 | 0.150 |
Why?
| | Drosophila melanogaster | 3 | 2005 | 4 | 0.150 |
Why?
| | Transcobalamins | 1 | 2016 | 2 | 0.150 |
Why?
| | Cytoplasm | 1 | 2016 | 7 | 0.150 |
Why?
| | Thyroid Gland | 1 | 2016 | 3 | 0.140 |
Why?
| | Congenital Hypothyroidism | 1 | 2016 | 4 | 0.140 |
Why?
| | Cell Separation | 1 | 2016 | 5 | 0.140 |
Why?
| | Genetic Heterogeneity | 1 | 2016 | 5 | 0.140 |
Why?
| | Receptor, Melatonin, MT1 | 1 | 2016 | 1 | 0.140 |
Why?
| | HIV Infections | 1 | 1998 | 140 | 0.140 |
Why?
| | Azacitidine | 2 | 2018 | 4 | 0.140 |
Why?
| | Europe | 3 | 2016 | 33 | 0.140 |
Why?
| | Gene-Environment Interaction | 1 | 2015 | 13 | 0.140 |
Why?
| | Neuromyelitis Optica | 1 | 2015 | 1 | 0.140 |
Why?
| | Histocompatibility Antigens | 1 | 2015 | 2 | 0.140 |
Why?
| | Diabetes, Gestational | 1 | 2015 | 4 | 0.140 |
Why?
| | Mitochondrial Proteins | 4 | 2018 | 7 | 0.140 |
Why?
| | Dendritic Cells | 1 | 2015 | 6 | 0.140 |
Why?
| | Mutation, Missense | 1 | 2015 | 24 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 8 | 0.140 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2022 | 7 | 0.140 |
Why?
| | Data Anonymization | 1 | 2015 | 2 | 0.140 |
Why?
| | Oligodendroglioma | 1 | 2015 | 2 | 0.140 |
Why?
| | Osteogenesis | 1 | 2015 | 6 | 0.140 |
Why?
| | Calcification, Physiologic | 1 | 2015 | 3 | 0.130 |
Why?
| | Prednisone | 1 | 2015 | 12 | 0.130 |
Why?
| | Bacterial Infections | 1 | 2015 | 27 | 0.130 |
Why?
| | Cholesterol, HDL | 1 | 2015 | 9 | 0.130 |
Why?
| | Triglycerides | 1 | 2015 | 20 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2015 | 15 | 0.130 |
Why?
| | Antirheumatic Agents | 1 | 2015 | 14 | 0.130 |
Why?
| | HeLa Cells | 2 | 2018 | 15 | 0.130 |
Why?
| | Colonic Neoplasms | 1 | 2015 | 7 | 0.130 |
Why?
| | Femur | 3 | 2009 | 10 | 0.130 |
Why?
| | Methionine | 2 | 2019 | 6 | 0.130 |
Why?
| | Immunoglobulin E | 1 | 2015 | 22 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 34 | 0.130 |
Why?
| | DNA Footprinting | 1 | 2014 | 1 | 0.130 |
Why?
| | Transcriptional Activation | 2 | 2015 | 8 | 0.130 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 27 | 0.130 |
Why?
| | Genotyping Techniques | 1 | 2014 | 21 | 0.130 |
Why?
| | 3' Untranslated Regions | 3 | 2013 | 10 | 0.120 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2013 | 1 | 0.120 |
Why?
| | Disease | 2 | 2012 | 7 | 0.120 |
Why?
| | X Chromosome Inactivation | 1 | 2013 | 3 | 0.120 |
Why?
| | Chromosomes, Human, X | 1 | 2013 | 5 | 0.120 |
Why?
| | Protein Isoforms | 2 | 2013 | 16 | 0.120 |
Why?
| | Chromosome Aberrations | 1 | 2013 | 5 | 0.120 |
Why?
| | Trypanosoma brucei brucei | 1 | 2013 | 1 | 0.120 |
Why?
| | RNA, Protozoan | 1 | 2013 | 1 | 0.120 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2013 | 1 | 0.120 |
Why?
| | RNA Stability | 1 | 2013 | 4 | 0.120 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2013 | 1 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2013 | 1 | 0.120 |
Why?
| | Transcription Initiation Site | 1 | 2013 | 2 | 0.120 |
Why?
| | Hypertension | 1 | 2014 | 59 | 0.120 |
Why?
| | Menarche | 1 | 2013 | 3 | 0.120 |
Why?
| | BRCA1 Protein | 1 | 2013 | 8 | 0.120 |
Why?
| | Microfilament Proteins | 2 | 2010 | 12 | 0.120 |
Why?
| | Protein Biosynthesis | 1 | 2013 | 2 | 0.110 |
Why?
| | Sex Characteristics | 1 | 2012 | 13 | 0.110 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2018 | 33 | 0.110 |
Why?
| | Introns | 2 | 2010 | 7 | 0.110 |
Why?
| | Genetic Complementation Test | 2 | 2010 | 4 | 0.110 |
Why?
| | Lectins | 1 | 2012 | 2 | 0.110 |
Why?
| | Adipokines | 1 | 2012 | 2 | 0.110 |
Why?
| | Toll-Like Receptor 3 | 2 | 2023 | 6 | 0.110 |
Why?
| | Ovarian Neoplasms | 1 | 2013 | 132 | 0.110 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2011 | 1 | 0.100 |
Why?
| | Adrenergic beta-Agonists | 1 | 2011 | 5 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2011 | 11 | 0.100 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2010 | 7 | 0.100 |
Why?
| | Germ-Line Mutation | 1 | 2010 | 10 | 0.100 |
Why?
| | RNA Splicing | 1 | 2010 | 11 | 0.100 |
Why?
| | Dinoprostone | 1 | 2011 | 8 | 0.100 |
Why?
| | Apolipoproteins B | 1 | 2010 | 1 | 0.100 |
Why?
| | Metabolic Networks and Pathways | 1 | 2010 | 10 | 0.100 |
Why?
| | Cholesterol, LDL | 1 | 2010 | 7 | 0.100 |
Why?
| | Infant, Newborn | 3 | 2023 | 790 | 0.100 |
Why?
| | DNA Helicases | 2 | 2023 | 5 | 0.100 |
Why?
| | Zebrafish | 2 | 2022 | 6 | 0.100 |
Why?
| | Tissue Distribution | 1 | 2010 | 10 | 0.100 |
Why?
| | Cell Proliferation | 3 | 2019 | 55 | 0.090 |
Why?
| | HEK293 Cells | 2 | 2021 | 30 | 0.090 |
Why?
| | Genetic Linkage | 2 | 2002 | 12 | 0.090 |
Why?
| | Prognosis | 3 | 2017 | 209 | 0.090 |
Why?
| | Cell Culture Techniques | 1 | 2010 | 5 | 0.090 |
Why?
| | Adiponectin | 1 | 2009 | 3 | 0.090 |
Why?
| | Contractile Proteins | 1 | 2009 | 2 | 0.090 |
Why?
| | DNA, Complementary | 2 | 2009 | 8 | 0.090 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 2 | 0.090 |
Why?
| | DNA-Binding Proteins | 2 | 2020 | 35 | 0.090 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2009 | 3 | 0.090 |
Why?
| | Obesity | 3 | 2019 | 124 | 0.090 |
Why?
| | Lumbar Vertebrae | 4 | 2012 | 12 | 0.090 |
Why?
| | Principal Component Analysis | 1 | 2009 | 13 | 0.090 |
Why?
| | Nevus | 1 | 2009 | 1 | 0.090 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2009 | 3 | 0.090 |
Why?
| | Precancerous Conditions | 1 | 2009 | 6 | 0.090 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2009 | 5 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 99 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2009 | 8 | 0.090 |
Why?
| | Models, Statistical | 1 | 2009 | 34 | 0.090 |
Why?
| | CRISPR-Cas Systems | 2 | 2019 | 13 | 0.090 |
Why?
| | Molecular Chaperones | 1 | 2009 | 6 | 0.090 |
Why?
| | Nuclear Proteins | 2 | 2020 | 45 | 0.090 |
Why?
| | Transplantation, Homologous | 2 | 2019 | 20 | 0.090 |
Why?
| | Cytosine | 2 | 2021 | 4 | 0.090 |
Why?
| | Tissue Donors | 2 | 2019 | 28 | 0.090 |
Why?
| | Siblings | 2 | 2019 | 7 | 0.090 |
Why?
| | Alternative Splicing | 2 | 2020 | 17 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2023 | 11 | 0.090 |
Why?
| | Templates, Genetic | 2 | 2000 | 2 | 0.080 |
Why?
| | Age Factors | 1 | 2009 | 203 | 0.080 |
Why?
| | STAT4 Transcription Factor | 1 | 2008 | 3 | 0.080 |
Why?
| | Antibodies, Antinuclear | 1 | 2008 | 3 | 0.080 |
Why?
| | Interferon Regulatory Factors | 1 | 2008 | 4 | 0.080 |
Why?
| | Osteoprotegerin | 1 | 2008 | 1 | 0.080 |
Why?
| | LDL-Receptor Related Proteins | 1 | 2008 | 2 | 0.080 |
Why?
| | Leptin | 1 | 2008 | 3 | 0.080 |
Why?
| | Circadian Rhythm | 1 | 2008 | 8 | 0.080 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2008 | 7 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 10 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 76 | 0.080 |
Why?
| | Homozygote | 4 | 2010 | 18 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2008 | 29 | 0.080 |
Why?
| | Protein Binding | 2 | 2018 | 30 | 0.080 |
Why?
| | Cohort Studies | 3 | 2018 | 264 | 0.080 |
Why?
| | Computer Simulation | 2 | 2018 | 22 | 0.080 |
Why?
| | Receptors, Calcitriol | 1 | 2007 | 9 | 0.080 |
Why?
| | Signal Transduction | 1 | 2008 | 107 | 0.080 |
Why?
| | Receptors, Chemokine | 1 | 2006 | 1 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2019 | 14 | 0.070 |
Why?
| | Twins, Monozygotic | 2 | 2016 | 6 | 0.070 |
Why?
| | Ribosomal Proteins | 2 | 2018 | 4 | 0.070 |
Why?
| | Primary Cell Culture | 2 | 2017 | 5 | 0.070 |
Why?
| | Models, Biological | 1 | 2006 | 46 | 0.070 |
Why?
| | Animal Structures | 1 | 2005 | 1 | 0.070 |
Why?
| | Family Health | 3 | 2018 | 14 | 0.070 |
Why?
| | Risk | 2 | 2016 | 40 | 0.070 |
Why?
| | Genomic Instability | 2 | 2018 | 2 | 0.070 |
Why?
| | Coronary Disease | 2 | 2009 | 5 | 0.070 |
Why?
| | Glycoproteins | 2 | 2017 | 9 | 0.070 |
Why?
| | Retrospective Studies | 2 | 2021 | 1251 | 0.070 |
Why?
| | Dosage Compensation, Genetic | 1 | 2004 | 1 | 0.060 |
Why?
| | Genes, Insect | 1 | 2004 | 1 | 0.060 |
Why?
| | Animals, Genetically Modified | 1 | 2024 | 3 | 0.060 |
Why?
| | Drosophila | 1 | 2024 | 4 | 0.060 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2024 | 4 | 0.060 |
Why?
| | Quebec | 2 | 2018 | 4 | 0.060 |
Why?
| | Extracellular Matrix Proteins | 2 | 2015 | 13 | 0.060 |
Why?
| | Cations | 1 | 2023 | 2 | 0.060 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2023 | 2 | 0.060 |
Why?
| | Canada | 2 | 2016 | 31 | 0.060 |
Why?
| | Muscle Spasticity | 1 | 2023 | 3 | 0.060 |
Why?
| | Dichlorodiphenyl Dichloroethylene | 1 | 2023 | 1 | 0.060 |
Why?
| | DEAD-box RNA Helicases | 1 | 2023 | 3 | 0.060 |
Why?
| | Mammals | 1 | 2023 | 3 | 0.060 |
Why?
| | Leucovorin | 1 | 2023 | 2 | 0.060 |
Why?
| | Folate Receptor 1 | 1 | 2023 | 2 | 0.060 |
Why?
| | Syndrome | 1 | 2023 | 33 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 11 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2023 | 5 | 0.060 |
Why?
| | Chromosomes, Human, Pair 11 | 2 | 2016 | 3 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2003 | 3 | 0.060 |
Why?
| | Survival of Motor Neuron 1 Protein | 1 | 2023 | 2 | 0.060 |
Why?
| | Survival of Motor Neuron 2 Protein | 1 | 2023 | 2 | 0.060 |
Why?
| | Sequence Analysis | 1 | 2023 | 3 | 0.060 |
Why?
| | Cytokines | 1 | 2023 | 48 | 0.060 |
Why?
| | Homocysteine | 1 | 2003 | 1 | 0.060 |
Why?
| | Gene Dosage | 1 | 2023 | 8 | 0.060 |
Why?
| | Morpholinos | 1 | 2022 | 1 | 0.060 |
Why?
| | Research Design | 1 | 2023 | 64 | 0.060 |
Why?
| | Central Nervous System | 1 | 2022 | 7 | 0.060 |
Why?
| | Linear Models | 2 | 2013 | 55 | 0.060 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 9 | 0.060 |
Why?
| | Odds Ratio | 2 | 2016 | 53 | 0.060 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 31 | 0.060 |
Why?
| | Diet | 1 | 2003 | 54 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 9 | 0.050 |
Why?
| | Vitamins | 1 | 2022 | 10 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2022 | 47 | 0.050 |
Why?
| | Microsatellite Repeats | 2 | 2002 | 7 | 0.050 |
Why?
| | Causality | 1 | 2022 | 10 | 0.050 |
Why?
| | Vaccination | 1 | 2022 | 68 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2002 | 6 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2022 | 30 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2021 | 18 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2021 | 16 | 0.050 |
Why?
| | Laboratories | 1 | 2021 | 16 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 145 | 0.050 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.050 |
Why?
| | Y Chromosome | 1 | 2001 | 1 | 0.050 |
Why?
| | Amygdala | 1 | 2021 | 3 | 0.050 |
Why?
| | HLA-DQ Antigens | 2 | 2002 | 4 | 0.050 |
Why?
| | Genes, Reporter | 2 | 2012 | 11 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2021 | 33 | 0.050 |
Why?
| | Complement C6 | 1 | 2020 | 4 | 0.050 |
Why?
| | Complement C7 | 1 | 2020 | 4 | 0.050 |
Why?
| | RNA Nucleotidyltransferases | 1 | 2020 | 4 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2020 | 4 | 0.050 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2020 | 4 | 0.050 |
Why?
| | Perforin | 1 | 2020 | 4 | 0.050 |
Why?
| | Scavenger Receptors, Class A | 1 | 2020 | 5 | 0.050 |
Why?
| | GRB2 Adaptor Protein | 1 | 2020 | 5 | 0.050 |
Why?
| | STAT1 Transcription Factor | 1 | 2020 | 6 | 0.050 |
Why?
| | Germ Cells | 1 | 2020 | 5 | 0.050 |
Why?
| | Fathers | 1 | 2020 | 6 | 0.050 |
Why?
| | Databases, Factual | 1 | 2021 | 105 | 0.050 |
Why?
| | Gene Library | 1 | 2020 | 5 | 0.050 |
Why?
| | Fertility | 1 | 2020 | 15 | 0.050 |
Why?
| | Machine Learning | 1 | 2020 | 14 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2013 | 44 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 31 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2001 | 317 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2021 | 142 | 0.050 |
Why?
| | Bacteriophage T7 | 1 | 2000 | 1 | 0.050 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2000 | 2 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2000 | 19 | 0.050 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-5 | 2 | 2012 | 5 | 0.050 |
Why?
| | Viral Proteins | 1 | 2000 | 8 | 0.050 |
Why?
| | Pilot Projects | 1 | 2020 | 124 | 0.050 |
Why?
| | Femur Neck | 2 | 2012 | 6 | 0.050 |
Why?
| | Adipocytes | 1 | 2019 | 3 | 0.050 |
Why?
| | Body Fat Distribution | 1 | 2019 | 4 | 0.050 |
Why?
| | Histocompatibility | 1 | 2019 | 2 | 0.040 |
Why?
| | Regulatory Elements, Transcriptional | 1 | 2019 | 3 | 0.040 |
Why?
| | Disease Progression | 1 | 2019 | 104 | 0.040 |
Why?
| | Blood Glucose | 1 | 2019 | 53 | 0.040 |
Why?
| | Insulin | 1 | 2019 | 46 | 0.040 |
Why?
| | Bioethical Issues | 1 | 2019 | 3 | 0.040 |
Why?
| | Regression Analysis | 1 | 2019 | 56 | 0.040 |
Why?
| | Incidental Findings | 1 | 2019 | 8 | 0.040 |
Why?
| | Neurogenesis | 1 | 2019 | 2 | 0.040 |
Why?
| | Lysine | 1 | 2019 | 3 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 7 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 12 | 0.040 |
Why?
| | Lipids | 1 | 2019 | 7 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2019 | 7 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2019 | 23 | 0.040 |
Why?
| | Blood Cells | 1 | 2018 | 2 | 0.040 |
Why?
| | Nucleic Acid Conformation | 1 | 2018 | 1 | 0.040 |
Why?
| | Caco-2 Cells | 1 | 2018 | 1 | 0.040 |
Why?
| | HT29 Cells | 1 | 2018 | 1 | 0.040 |
Why?
| | MCF-7 Cells | 1 | 2018 | 4 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2018 | 6 | 0.040 |
Why?
| | K562 Cells | 1 | 2018 | 3 | 0.040 |
Why?
| | Neuropilin-2 | 1 | 2018 | 1 | 0.040 |
Why?
| | Serpin E2 | 1 | 2018 | 1 | 0.040 |
Why?
| | Immunity | 1 | 2018 | 1 | 0.040 |
Why?
| | Binding Sites | 1 | 2018 | 26 | 0.040 |
Why?
| | Receptors, LDL | 1 | 1998 | 1 | 0.040 |
Why?
| | Plasminogen Inactivators | 1 | 1998 | 1 | 0.040 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 1998 | 1 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 7 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2018 | 24 | 0.040 |
Why?
| | NF-kappa B | 1 | 2018 | 14 | 0.040 |
Why?
| | Collectins | 1 | 1998 | 1 | 0.040 |
Why?
| | HLA-DP beta-Chains | 1 | 2018 | 1 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 2018 | 2 | 0.040 |
Why?
| | DNA, Viral | 1 | 1998 | 13 | 0.040 |
Why?
| | INDEL Mutation | 1 | 2018 | 1 | 0.040 |
Why?
| | Genes, Switch | 1 | 2018 | 1 | 0.040 |
Why?
| | Myelin Basic Protein | 1 | 1998 | 2 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 19 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2018 | 54 | 0.040 |
Why?
| | Interferon-gamma | 1 | 1997 | 4 | 0.040 |
Why?
| | Diploidy | 1 | 2017 | 1 | 0.040 |
Why?
| | Physical Chromosome Mapping | 1 | 2017 | 1 | 0.040 |
Why?
| | Transcription Elongation, Genetic | 1 | 2017 | 1 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2017 | 3 | 0.040 |
Why?
| | Forelimb | 1 | 2017 | 1 | 0.040 |
Why?
| | Chondrogenesis | 1 | 2017 | 1 | 0.040 |
Why?
| | SOX9 Transcription Factor | 1 | 2017 | 1 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2017 | 5 | 0.040 |
Why?
| | Branchial Region | 1 | 2017 | 2 | 0.040 |
Why?
| | Host Cell Factor C1 | 1 | 2017 | 2 | 0.040 |
Why?
| | DNA-Directed DNA Polymerase | 1 | 1997 | 1 | 0.040 |
Why?
| | Nucleic Acid Hybridization | 1 | 1997 | 1 | 0.040 |
Why?
| | Craniofacial Abnormalities | 1 | 2017 | 10 | 0.040 |
Why?
| | Oligonucleotide Probes | 1 | 1997 | 4 | 0.040 |
Why?
| | Antigens, CD1 | 1 | 2017 | 1 | 0.040 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2017 | 3 | 0.040 |
Why?
| | Chromosomal Position Effects | 1 | 2017 | 3 | 0.040 |
Why?
| | Genes | 2 | 2012 | 9 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2017 | 7 | 0.040 |
Why?
| | Species Specificity | 1 | 2017 | 6 | 0.040 |
Why?
| | Fetal Blood | 1 | 2016 | 5 | 0.040 |
Why?
| | Internet | 1 | 2016 | 16 | 0.040 |
Why?
| | Sex Factors | 1 | 2017 | 71 | 0.040 |
Why?
| | HLA-DR2 Antigen | 1 | 1996 | 1 | 0.040 |
Why?
| | Fluorescence | 1 | 1996 | 5 | 0.040 |
Why?
| | Gene Amplification | 1 | 1996 | 4 | 0.040 |
Why?
| | HLA-DQ alpha-Chains | 1 | 1996 | 3 | 0.040 |
Why?
| | Risk Assessment | 1 | 2016 | 130 | 0.040 |
Why?
| | Twins, Dizygotic | 1 | 2015 | 3 | 0.040 |
Why?
| | Comorbidity | 1 | 2016 | 61 | 0.040 |
Why?
| | Blood | 1 | 2015 | 10 | 0.030 |
Why?
| | Aquaporin 4 | 1 | 2015 | 1 | 0.030 |
Why?
| | Time Factors | 1 | 2016 | 241 | 0.030 |
Why?
| | Lung | 2 | 2006 | 65 | 0.030 |
Why?
| | 5-Methylcytosine | 1 | 2015 | 1 | 0.030 |
Why?
| | snRNP Core Proteins | 1 | 2015 | 2 | 0.030 |
Why?
| | Mycobacterium tuberculosis | 1 | 2015 | 4 | 0.030 |
Why?
| | Tuberculosis | 1 | 2015 | 4 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2015 | 11 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2015 | 55 | 0.030 |
Why?
| | Bone Development | 1 | 2015 | 4 | 0.030 |
Why?
| | Down-Regulation | 1 | 2015 | 14 | 0.030 |
Why?
| | Bone Diseases, Developmental | 1 | 2015 | 3 | 0.030 |
Why?
| | Tubulin | 1 | 2015 | 4 | 0.030 |
Why?
| | Administration, Oral | 1 | 2015 | 59 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2015 | 8 | 0.030 |
Why?
| | Smoking | 1 | 2015 | 69 | 0.030 |
Why?
| | Genetics, Population | 2 | 2005 | 11 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2014 | 3 | 0.030 |
Why?
| | Thiamine | 1 | 2014 | 2 | 0.030 |
Why?
| | Retinoblastoma-Like Protein p130 | 1 | 2013 | 1 | 0.030 |
Why?
| | Gene Fusion | 1 | 2013 | 2 | 0.030 |
Why?
| | Genes, X-Linked | 1 | 2013 | 3 | 0.030 |
Why?
| | Multigene Family | 1 | 2013 | 7 | 0.030 |
Why?
| | Blood Pressure | 1 | 2014 | 56 | 0.030 |
Why?
| | Trypanosoma | 1 | 2013 | 1 | 0.030 |
Why?
| | Protozoan Proteins | 1 | 2013 | 1 | 0.030 |
Why?
| | Regulon | 1 | 2013 | 1 | 0.030 |
Why?
| | ELAV Proteins | 1 | 2013 | 1 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2013 | 45 | 0.030 |
Why?
| | Nucleotide Motifs | 1 | 2013 | 3 | 0.030 |
Why?
| | Sweden | 2 | 2007 | 27 | 0.030 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2013 | 2 | 0.030 |
Why?
| | Recurrence | 1 | 2013 | 115 | 0.030 |
Why?
| | BRCA2 Protein | 1 | 2013 | 8 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 11 | 0.030 |
Why?
| | Polyribosomes | 1 | 2013 | 2 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 57 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 13 | 0.030 |
Why?
| | Luciferases | 1 | 2012 | 6 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2012 | 4 | 0.030 |
Why?
| | Macrophages, Alveolar | 1 | 2012 | 2 | 0.030 |
Why?
| | Spectrin | 1 | 2012 | 2 | 0.030 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2012 | 2 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2012 | 11 | 0.030 |
Why?
| | HLA-DR Antigens | 2 | 2002 | 7 | 0.030 |
Why?
| | Vital Capacity | 1 | 2011 | 6 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2011 | 10 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 16 | 0.030 |
Why?
| | Adenoma | 1 | 2010 | 2 | 0.020 |
Why?
| | Spindle Apparatus | 1 | 2010 | 3 | 0.020 |
Why?
| | 2',5'-Oligoadenylate Synthetase | 1 | 2010 | 1 | 0.020 |
Why?
| | Gene Order | 1 | 2010 | 1 | 0.020 |
Why?
| | Alkyl and Aryl Transferases | 1 | 2010 | 2 | 0.020 |
Why?
| | Chromosome Disorders | 1 | 2010 | 6 | 0.020 |
Why?
| | Karyotyping | 1 | 2010 | 8 | 0.020 |
Why?
| | Mosaicism | 1 | 2010 | 8 | 0.020 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2010 | 5 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2010 | 8 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2010 | 2 | 0.020 |
Why?
| | Quantitative Trait, Heritable | 1 | 2010 | 2 | 0.020 |
Why?
| | Multifactorial Inheritance | 1 | 2010 | 10 | 0.020 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2010 | 2 | 0.020 |
Why?
| | Filamins | 1 | 2009 | 2 | 0.020 |
Why?
| | Gene Silencing | 1 | 2010 | 13 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2009 | 1 | 0.020 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2009 | 2 | 0.020 |
Why?
| | Italy | 1 | 2009 | 3 | 0.020 |
Why?
| | Melanoma | 1 | 2009 | 4 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 27 | 0.020 |
Why?
| | Transfection | 1 | 2009 | 19 | 0.020 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2008 | 10 | 0.020 |
Why?
| | Hong Kong | 1 | 2007 | 2 | 0.020 |
Why?
| | Spinal Fractures | 1 | 2007 | 3 | 0.020 |
Why?
| | Pelvic Bones | 1 | 2007 | 8 | 0.020 |
Why?
| | Gene Components | 1 | 2006 | 1 | 0.020 |
Why?
| | Mice, Congenic | 1 | 2006 | 2 | 0.020 |
Why?
| | Crosses, Genetic | 1 | 2006 | 4 | 0.020 |
Why?
| | Genome, Insect | 1 | 2005 | 1 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2005 | 4 | 0.020 |
Why?
| | California | 1 | 2005 | 14 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2005 | 36 | 0.020 |
Why?
| | Animals, Wild | 1 | 2004 | 1 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2004 | 4 | 0.020 |
Why?
| | Animals, Laboratory | 1 | 2004 | 2 | 0.020 |
Why?
| | Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 1 | 0.010 |
Why?
| | Nutritional Status | 1 | 2003 | 14 | 0.010 |
Why?
| | HLA-DR Serological Subtypes | 1 | 2002 | 1 | 0.010 |
Why?
| | Biomarkers | 1 | 2003 | 120 | 0.010 |
Why?
| | HLA-DQ beta-Chains | 1 | 2002 | 2 | 0.010 |
Why?
| | HLA-DRB1 Chains | 1 | 2002 | 5 | 0.010 |
Why?
| | Hungary | 1 | 2001 | 1 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1998 | 10 | 0.010 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 1997 | 1 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 1 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1997 | 4 | 0.010 |
Why?
| | Receptors, Interleukin-1 | 1 | 1997 | 9 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|